lysosome, it binds to neuraminidase and bgalactosidase to activate the former and stabilize the latter, functions that led to the term "lysosomal protective protein." It also possesses serine carboxypeptidase activity at acidic pH as well as deamidase and esterase activities at neutral pH. Mutations that disrupt its "protective" functions are known to cause the lysosomal storage disease, galactosialidosis, in humans (summarized by Hiraiwa [1] ). However, its enzymatic activity has garnered the most attention in recent years. Although localized to lysosomes intracellularly, cathepsin A can also be secreted.
Extracellularly, it is capable of degrading many bioactive peptides that function in the cardiovascular system, including endothelin-1, bradykinin, and angiotensin I. Because the enzymatic activity of cathepsin A can be targeted separately from its "protective" functions (2), there has been interest for at least a decade in clinically targeting cathepsin A in patients with cardiovascular disease, and novel bamino acid inhibitors were synthesized for this purpose (3).
In the paper by Hohl et al. (4) in this issue of JACC:
Basic to Translational Science, the investigators examine the effect of 1 of these inhibitors, SAR164653
cardiomyopathy. Analysis of left ventricle specimens of patients with end-stage ischemic cardiomyopathy revealed significant increases in cathepsin A mRNA and protein levels (w50% increase over tissue from healthy donor hearts), although details of these patients were not available. Using a rat model of myocardial infarction, cathepsin A mRNA levels in the remote left ventricular myocardium and left atrial myocardium were significantly increased 8 weeks after left anterior descending artery ligation (1.5-and 1.8-fold, respectively). Using an ischemia/reperfusion rat model (30-min ischemia followed by 10-week reperfusion), these increases were 1.7-and 2.9-fold, respectively. The up-regulated cathepsin A levels were associated with increased atrial natriuretic peptide mRNA levels. Treatment of the ischemia/ reperfusion rats with SAR164653 had no effect on infarct size or normalized heart weight, but did improve ejection fraction and reduce plasma brain natriuretic peptide levels. Magnetic resonance imaging analysis revealed better contractility in the SAR164653-treated rats than in the placebo-treated rats, which seemed to be caused by preservation of remote myocardium with SAR164653 treatment (i.e., there was better wall motion in these areas).
Regarding the left atrium, SAR164653 did not affect chamber dimensions in the ischemia/reperfusion rats, but fractional shortening was significantly higher compared with that of the placebo-treated controls.
With respect to left atrial remodeling at 10 weeks, Science author instructions page. 
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